Clinical Trial Detail

NCT ID NCT01061515
Title Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Washington University School of Medicine
Indications

appendix adenocarcinoma

peritoneal carcinoma

colorectal adenocarcinoma

Therapies

Capecitabine

Bevacizumab

Oxaliplatin

Age Groups: adult

No variant requirements are available.